GPT-Rosalind Lands: What OpenAI’s First Domain-Specific Life Sciences Model, the Codex Life Sciences Plugin & the Trusted Access Program Actually Mean
Quick Links: Knowledge Base, Podcast, and Social
Knowledge Base — search and filter every article and podcast episode by topic, section, and keyword: kb.onhealthcare.tech
Listen to the Podcast — every article is also available as an audio episode. Free subscribers get the public episodes; paid subscribers get the full archive including subscriber-only episodes. Listen on Apple Podcasts, Spotify, or browse all episodes on the Substack Podcast page.
For paid subscribers — your subscription unlocks the entire research archive (538+ deep-dives), every paid podcast episode, and full search inside the Knowledge Base. To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).
For free subscribers — free posts and free podcast episodes are always public on Apple/Spotify and Substack. Upgrade any time at onhealthcare.tech/subscribe to access the paid archive and paid episodes.
Follow on Social — X · YouTube · TikTok · Instagram
Table of Contents
What actually shipped on April 16
Benchmarks, with the appropriate skepticism
The plugin is the real story
Trusted access, biosecurity, and why the gate matters
Where this lands inside the pharma stack
What gets compressed, what gets created, what gets killed
Read-throughs for tools, data, and services companies
Angel and seed-stage implications
The quiet part about moats
Caveats, open questions, and the boring stuff nobody wants to talk about
So what now
Abstract
- OpenAI shipped GPT-Rosalind on April 16, 2026, its first purpose-built domain model, aimed at biochemistry, genomics, and protein engineering
- Access is gated via a trusted-access program; launch partners include Amgen, Moderna, Thermo Fisher Scientific, Allen Institute, plus a Los Alamos collab on protein and catalyst design
- Claimed benchmark results: 0.751 pass rate on BixBench, beats GPT-5.4 on 6 of 11 LABBench2 tasks, and in a Dyno Therapeutics eval on unpublished RNA sequences, best-of-10 submissions cleared the 95th percentile of human experts on sequence-to-function prediction and roughly 84th percentile on sequence generation
- A Life Sciences research plugin for Codex connects the model to 50+ scientific tools and public bio databases, which is arguably more commercially important than the model weights themselves
- Preview phase does not consume tokens or credits for approved orgs, meaning the effective price is zero for the enterprise tier, which will distort willingness-to-pay data across the entire biotech software market for roughly 6 to 12 months
- Read-through for founders: data-access wrappers, lit-review tools, and protocol-design copilots with no proprietary data are now at existential risk; differentiated wet-lab data, closed-loop experimentation, regulated workflows, and vertical systems of record are relatively safer
- Read-through for angels: pause any check into a pure RAG-over-PubMed startup, underwrite biotech software against a post-Rosalind baseline rather than a GPT-4-era baseline, and lean into companies producing new, non-public scientific data
- Caveats: dual-use risk is non-trivial, no fully AI-discovered drug has cleared phase 3, and OpenAI’s benchmark numbers are self-reported against evals where OpenAI had training-time knowledge of the tasks
What actually shipped on April 16
OpenAI pushed out three things in a single announcement, and the health tech crowd keeps conflating them. Separating the three is how the analysis gets interesting.
The first is GPT-Rosalind itself, a frontier reasoning model in a new Life Sciences series. It is designed to support evidence synthesis, hypothesis generation, experimental planning, and multi-step scientific workflows across biochemistry, genomics, and protein engineering.  Named after Rosalind Franklin, which is a nice bit of historical housekeeping given the Nobel committee’s 1962 miss. The model is available in ChatGPT, Codex, and the API, but you cannot just sign up for it.
The second is the gating layer, which OpenAI calls the trusted access program. Eligibility is restricted to qualified enterprise customers in the US working on health-relevant research, with governance and safety oversight controls in place. Launch partners named publicly are Amgen, Moderna, Thermo Fisher Scientific, and the Allen Institute, plus an existing collaboration with Los Alamos National Laboratory on AI-guided protein and catalyst design. During the preview, usage does not consume existing credits or tokens for approved orgs, subject to abuse guardrails. The pricing part is worth staring at for a minute. OpenAI is effectively giving the model away to pharma at the moment, which is a fairly aggressive land grab and is going to wreck price discovery for every startup trying to sell AI-for-biotech software to the same buyers.
The third is the Life Sciences research plugin for Codex, published to GitHub. The plugin connects models to over 50 scientific tools and data sources,  including human genetics, functional genomics, protein structure, and clinical evidence data. Quietly, OpenAI said it is also making the connectors and the plugin more broadly available for use with mainline models, not just Rosalind. That matters more than the model itself. More on that below.
Benchmarks, with the appropriate skepticism
The benchmark numbers are noteworthy but worth reading carefully, because every model vendor publishes whatever makes their thing look good.
